CA2620219A1 - Organoleptically acceptable ibuprofen oral dosage formulations, methods of making and using the same - Google Patents

Organoleptically acceptable ibuprofen oral dosage formulations, methods of making and using the same Download PDF

Info

Publication number
CA2620219A1
CA2620219A1 CA002620219A CA2620219A CA2620219A1 CA 2620219 A1 CA2620219 A1 CA 2620219A1 CA 002620219 A CA002620219 A CA 002620219A CA 2620219 A CA2620219 A CA 2620219A CA 2620219 A1 CA2620219 A1 CA 2620219A1
Authority
CA
Canada
Prior art keywords
ibuprofen
formulation
acid
cyclodextrin
masking component
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002620219A
Other languages
English (en)
French (fr)
Inventor
Toru Hibi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teikoku Pharma USA Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2620219A1 publication Critical patent/CA2620219A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/534—Mentha (mint)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
CA002620219A 2005-11-02 2006-10-17 Organoleptically acceptable ibuprofen oral dosage formulations, methods of making and using the same Abandoned CA2620219A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US73312705P 2005-11-02 2005-11-02
US60/733,127 2005-11-02
US81041706P 2006-06-01 2006-06-01
US60/810,417 2006-06-01
PCT/US2006/041024 WO2007055887A1 (en) 2005-11-02 2006-10-17 Organoleptically acceptable ibuprofen oral dosage formulations, methods of making and using the same

Publications (1)

Publication Number Publication Date
CA2620219A1 true CA2620219A1 (en) 2007-05-18

Family

ID=38023574

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002620219A Abandoned CA2620219A1 (en) 2005-11-02 2006-10-17 Organoleptically acceptable ibuprofen oral dosage formulations, methods of making and using the same

Country Status (12)

Country Link
US (1) US20070098789A1 (https=)
EP (1) EP1942877A4 (https=)
JP (2) JP2009514857A (https=)
KR (1) KR20080034166A (https=)
CN (1) CN103622926A (https=)
AR (1) AR056749A1 (https=)
AU (2) AU2006312119B2 (https=)
BR (1) BRPI0618273A2 (https=)
CA (1) CA2620219A1 (https=)
RU (2) RU2008116871A (https=)
TW (1) TW200733954A (https=)
WO (1) WO2007055887A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2620219A1 (en) * 2005-11-02 2007-05-18 Teikoku Pharma Usa, Inc. Organoleptically acceptable ibuprofen oral dosage formulations, methods of making and using the same
AU2007308986A1 (en) * 2006-10-25 2008-05-02 Mcneil-Ppc, Inc. Ibuprofen composition
JP5821247B2 (ja) * 2010-04-07 2015-11-24 大正製薬株式会社 イブプロフェンの昇華抑制方法
EP3178470A1 (en) * 2011-04-11 2017-06-14 Vitux Group AS Oral pharmaceutical dispersion compositions
CN102258490B (zh) * 2011-07-01 2012-10-03 中美天津史克制药有限公司 布洛芬咀嚼片
US9914968B2 (en) 2012-09-26 2018-03-13 Cepheid Honeycomb tube
FR2997856B1 (fr) * 2012-11-14 2015-04-24 Pf Medicament Pastille medicamenteuse a base d'ibuprofene sodique dihydrate
CN103690474B (zh) * 2013-12-04 2015-09-30 郑州大明药物科技有限公司 布洛芬乳膏的制备方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8623557D0 (en) * 1986-10-01 1986-11-05 Boots Co Plc Therapeutic agents
GB8813682D0 (en) * 1988-06-09 1988-07-13 Reckitt & Colmann Prod Ltd Pharmaceutical compositions
CH677606A5 (https=) * 1988-07-12 1991-06-14 Aesculapius Pharma Sa
US4916161A (en) * 1988-10-25 1990-04-10 Bristol-Myers Squibb Taste-masking pharmaceutical agents
US5055461A (en) * 1989-02-15 1991-10-08 Richardson-Vicks Inc. Anesthetic oral compositions and methods of use
JPH0426618A (ja) * 1990-05-21 1992-01-29 Japan Tobacco Inc トローチ剤
US5024997A (en) * 1990-06-22 1991-06-18 American Home Products Corporation Palatable ibuprofen solutions
DE69331839T2 (de) * 1992-01-29 2002-12-12 Takeda Chemical Industries, Ltd. Schnellösliche Tablette und ihre Herstellung
GB9207990D0 (en) * 1992-04-10 1992-05-27 Smithkline Beecham Plc Pharmaceutical composition
JPH08509725A (ja) * 1993-04-30 1996-10-15 ザ、プロクター、エンド、ギャンブル、カンパニー コートされた医薬組成物
US5866162A (en) * 1993-08-10 1999-02-02 Smithkline Beecham P.L.C. Pharmaceutical composition containing a drug/β-cyclodextrin complex in combination with an acid-base couple
US5616344A (en) * 1994-06-14 1997-04-01 Fuisz Technologies Ltd. Apparatus and process for strengthening low density compression dosage units and product therefrom
US5560913A (en) * 1995-01-27 1996-10-01 The Procter & Gamble Company Pharmaceutical compositions
TW442287B (en) * 1995-06-13 2001-06-23 American Home Produits Corp Organoleptically acceptable oral pharmaceutical composition comprising the S(+)1,8-diethyl-1-1,3,4,9-tetrahydropyrano[3,4-b] indole-1-acetic acid (Etodolac)
ATE210428T1 (de) * 1995-10-17 2001-12-15 Reckitt Benckiser Healthcare Geschmacksmaskierte wässrige lösungen enthaltend ibuprofen und menthol
GB9523833D0 (en) * 1995-11-22 1996-01-24 Boots Co Plc Medical treatment
US5912007A (en) * 1996-02-29 1999-06-15 Warner-Lambert Company Delivery system for the localized administration of medicaments to the upper respiratory tract and methods for preparing and using same
AU3444297A (en) * 1996-07-12 1998-02-09 Novartis Consumer Health S.A. Oral pharmaceutical combinations of nsaids with terpenoids
GB9710521D0 (en) * 1997-05-22 1997-07-16 Boots Co Plc Process
US6517870B1 (en) * 1998-04-29 2003-02-11 Sumitomo Pharmaceuticals Company, Limited Oral formulation comprising biguanide and an organic acid
US20020110581A1 (en) * 1999-04-06 2002-08-15 Ream Ronald L. Over-coated product including consumable center and medicament
US20050042271A1 (en) * 1999-11-19 2005-02-24 Xel Herbaceuticals, Inc . Transdermal delivery system for alkaloids of aconitum species
ES2171110B1 (es) * 2000-03-03 2003-06-16 Aplicaciones Farmacodinamicas Composicion farmaceutica a base de ibuprofeno y procedimiento para su preparacion.
WO2003009834A1 (en) * 2000-08-17 2003-02-06 Battey Alyce S Oral delivery of pharmaceuticals via encapsulation
EA005494B1 (ru) * 2000-08-25 2005-02-24 Кова Компани, Лтд. Жидкая загрузочная композиция для капсул с ибупрофеном и препарат в виде капсул
IT1319229B1 (it) * 2000-10-20 2003-09-26 Savio Macchine Tessili Spa Dispositivo portarocche perfezionato per avvolgimento di filato conpressione regolata, particolarmente per ritorcitoi a doppia torsione.
EP1391201A4 (en) * 2001-05-25 2004-06-30 Ssp Co Ltd MEDICAL COMPOSITIONS
US8859028B2 (en) * 2002-06-14 2014-10-14 Cereal Ingredients, Inc. Coated food particle and method for making a swirl
GB0217382D0 (en) * 2002-07-26 2002-09-04 Pfizer Ltd Process for making orally consumable dosage forms
US20040071852A1 (en) * 2002-10-09 2004-04-15 Yael Vodovotz Compositions and processes for making high soy protein-containing bakery products
ES2533469T3 (es) * 2002-10-11 2015-04-10 Novozymes A/S Método de preparación de un producto tratado con calor
JP4815867B2 (ja) * 2004-05-11 2011-11-16 大正製薬株式会社 安定化された固形製剤
US20060263475A1 (en) * 2004-08-25 2006-11-23 Cadbury Adams Usa, Llc. Center-filled chewing gum composition
EP1835886A1 (en) * 2004-12-23 2007-09-26 Warner-Lambert Company LLC Orally disintegrating pharmaceutical compositions with sensory cue agents
CA2620219A1 (en) * 2005-11-02 2007-05-18 Teikoku Pharma Usa, Inc. Organoleptically acceptable ibuprofen oral dosage formulations, methods of making and using the same

Also Published As

Publication number Publication date
RU2012138581A (ru) 2014-03-20
AU2006312119B2 (en) 2010-04-29
WO2007055887A1 (en) 2007-05-18
EP1942877A4 (en) 2011-09-14
BRPI0618273A2 (pt) 2011-08-23
EP1942877A1 (en) 2008-07-16
JP2012255018A (ja) 2012-12-27
RU2008116871A (ru) 2009-12-10
TW200733954A (en) 2007-09-16
CN103622926A (zh) 2014-03-12
AR056749A1 (es) 2007-10-24
AU2006312119A1 (en) 2007-05-18
JP2009514857A (ja) 2009-04-09
AU2010202050A1 (en) 2010-06-10
KR20080034166A (ko) 2008-04-18
US20070098789A1 (en) 2007-05-03

Similar Documents

Publication Publication Date Title
AU2010202050A1 (en) Organoleptically acceptable ibuprofen oral dosage formulations, methods of making and using the same
EP2512446B1 (en) Composition of dexibuprofen transdermal hydrogel
US7138394B2 (en) Vehicle for topical delivery of anti-inflammatory compounds
WO2008001325A2 (en) Herbal compositions for the treatment of diseases of the oral cavity
JP5360368B2 (ja) 服用感が改善された経口用アミノ酸製剤
JP6765299B2 (ja) 水性製剤
DK2833880T3 (en) Oral solid dosage composition with ibuprofen comprising a methacrylic acid copolymer
JP2001010977A (ja) 経口用組成物
JP5577168B2 (ja) 経口用医薬組成物
CA2444839A1 (en) Ambroxol for the treatment of inflammation in the pharynx
HK1191560A (en) Organoleptically acceptable ibuprofen oral dosage formulations, methods of making and using the same
CN101262854A (zh) 感官上可接受的布洛芬口服给药制剂、制备和使用它的方法
CN104640537A (zh) 用于口服剂型的低熔点丙酸衍生物粒子
WO2019105957A1 (en) Stable liquid composition of ketoprofen, salts and enantiomers thereof
JP7304049B2 (ja) タイトジャンクションの緩和剤、該緩和剤を含む化合物の吸収促進剤、並びに、該緩和剤を有効成分として含む医薬組成物、医薬部外品組成物、化粧品組成物および食品組成物
JP7550014B2 (ja) 医薬組成物
US20230233641A1 (en) Oral gel compositions
KR20190078455A (ko) 플루르비프로펜 함유 스프레이 조성물 및 그 제조방법
JP2004331660A5 (https=)
JP7214331B2 (ja) 医薬組成物
CN104640570B (zh) 包含低熔点丙酸衍生物颗粒的混悬药物制剂
AU2007264709B2 (en) Herbal compositions for the treatment of diseases of the oral cavity
CN104640571A (zh) 包含低熔点丙酸衍生物颗粒的缓释口服剂型
CN105168155A (zh) 可直接压制的丙酸衍生物颗粒
MXPA03009443A (es) Ambroxol para el tratamiento de inflamacion en la faringe.

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20140912